Healthcare provider profile · identity verified

Frank J Guidry, M.D.

Family Practice · NEW ORLEANS, LA · NPI 1104870591

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	547	167
Amlodipine Besylate	Amlodipine Besylate	408	135
Levothyroxine Sodium	Levothyroxine Sodium	193	51
Hydrochlorothiazide	Hydrochlorothiazide	192	67
Lisinopril	Lisinopril	189	67
Pantoprazole Sodium	Pantoprazole Sodium	179	61
Losartan Potassium	Losartan Potassium	168	55
Gabapentin	Gabapentin	156	54
Metformin Hcl	Metformin Hcl	155	51
Glimepiride	Glimepiride	122	40
Metoprolol Succinate	Metoprolol Succinate	119	38
Trazodone Hcl	Trazodone Hcl	111	36
Alprazolam	Alprazolam	103	18
Simvastatin	Simvastatin	101	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	94	27
Furosemide	Furosemide	93	32
Omeprazole	Omeprazole	93	29
Allopurinol	Allopurinol	90	29
Rosuvastatin Calcium	Rosuvastatin Calcium	87	27
Potassium Chloride	Potassium Chloride	85	30
Citalopram Hbr	Citalopram Hydrobromide	81	25
Olmesartan Medoxomil	Olmesartan Medoxomil	78	19
Metformin Hcl Er	Metformin Hcl	75	19
Benazepril Hcl	Benazepril Hcl	70	22
Lorazepam	Lorazepam	69	14
Carvedilol	Carvedilol	65	22
Eliquis	Apixaban	65	16
Escitalopram Oxalate	Escitalopram Oxalate	65	20
Tramadol Hcl	Tramadol Hcl	65	12
Montelukast Sodium	Montelukast Sodium	64	26
Tamsulosin Hcl	Tamsulosin Hcl	62	19
Buspirone Hcl	Buspirone Hcl	59	18
Metoprolol Tartrate	Metoprolol Tartrate	59	21
Clopidogrel	Clopidogrel Bisulfate	58	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	20
Meloxicam	Meloxicam	58	19
Albuterol Sulfate Hfa	Albuterol Sulfate	57	29
Amitriptyline Hcl	Amitriptyline Hcl	53	12
Fluticasone Propionate	Fluticasone Propionate	53	24
Mounjaro	Tirzepatide	50	suppressed
Pravastatin Sodium	Pravastatin Sodium	47	17
Clonidine Hcl	Clonidine Hcl	46	14
Zolpidem Tartrate	Zolpidem Tartrate	45	suppressed
Sertraline Hcl	Sertraline Hcl	43	14
Atenolol	Atenolol	40	14
Mirtazapine	Mirtazapine	39	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	38	12
Esomeprazole Magnesium	Esomeprazole Magnesium	35	11
Baclofen	Baclofen	34	suppressed
Colchicine	Colchicine	34	14
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Finasteride	Finasteride	33	13
Januvia	Sitagliptin Phosphate	32	suppressed
Synthroid	Levothyroxine Sodium	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	14
Valsartan	Valsartan	30	11
Methocarbamol	Methocarbamol	28	12
Clonazepam	Clonazepam	27	suppressed
Ozempic	Semaglutide	27	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	26	suppressed
Diazepam	Diazepam	26	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	25	suppressed
Fenofibrate	Fenofibrate	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Ibandronate Sodium	Ibandronate Sodium	24	suppressed
Ibuprofen	Ibuprofen	24	12
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	12
Celecoxib	Celecoxib	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	19	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Promethazine Hcl	Promethazine Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Alendronate Sodium	Alendronate Sodium	15	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Risperidone	Risperidone	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	14	suppressed
Cilostazol	Cilostazol	14	suppressed
Glipizide	Glipizide	14	suppressed
Propranolol Hcl Er	Propranolol Hcl	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Estradiol	Estradiol	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Paroxetine Cr	Paroxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error